ホーム>>Signaling Pathways>> GPCR/G protein>> Glucocorticoid Receptor>>Budesonide

Budesonide

カタログ番号GC11897

吸入グルココルチカルステロイドであるブデソニドは、経口活性グルココルチコイド受容体アゴニストです。

Products are for research use only. Not for human use. We do not sell to patients.

Budesonide 化学構造

Cas No.: 51333-22-3

サイズ 価格 在庫数 個数
10mM (in 1mL DMSO)
$37.00
在庫あり
50mg
$48.00
在庫あり

Tel:(909) 407-4943 Email: sales@glpbio.com

顧客レビュー

カスタマーレビューに基づきます。

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Budesonide is an anti-inflammatory corticosteroid [1].

Budesonide has shown the potent glucocorticoid activity and little mineralocorticoid activity. In addition, Budesonide has been reported to have a wide range of inhibitory activities against multiple cells types and mediators involved in allergic and nonallergic-mediated inflammatory. Besides, the anti-inflammatory action of budesonide has been revealed to contribute to the efficacy in asthma. Apart from these, orally inhaled budesonide has been found to be rapidly absorbed in the lungs and that peak concentration is typically reached within 20 minutes. The results have been exhibited that peak plasma concentration is achieved in about 1 to 2 h and the absolute systemic availability is 6%-13% after oral administration of budesonide [1].

References:
[1] Ricardo Zollner1*, Eduardo Abib Junior1,2*, Luciana Fernandes Duarte2, Maurício Wesley Perroud2andAntonioRicardo Amarante2. Bioequivalency Study for Inhaled Drugs: A Pharmacodynamic Approac. Bioequivalence & Bioavailability

レビュー

Review for Budesonide

Average Rating: 5 ★★★★★ (Based on Reviews and 37 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Budesonide

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.